Anti-CD38 binding domains

Patent metadata

Field	Value
Publication number	US-12312411-B2
Application number	US-202217810377-A
Country	US
Kind code	B2
Filing date	Jul 1, 2022
Priority date	Jan 23, 2019
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

First claim

The invention claimed is:

1. A composition comprising an anti-CD38-antigen binding domain that comprises a variable heavy domain (VH) comprising the sequence of SEQ ID NO: 9 and a variable light domain (VL) comprising the sequence of SEQ ID NO:13.

2. A composition comprising an anti-CD38-antigen binding domain that comprises a VH comprising the sequence of SEQ ID NO:17 and a VL comprising the sequence of SEQ ID NO:21.

3. A composition comprising an anti-CD38-antigen binding domain that comprises a VH comprising the sequence of SEQ ID NO: 53 and a VL comprising the sequence of SEQ ID NO: 57.

4. The composition according to claim 1 , wherein said VH and said VL are in a single polypeptide.

5. The composition according to claim 4 wherein, said polypeptide comprises a scFv linker and said polypeptide has the orientation from N- to C-terminal of VL-scFv linker-VH.

6. A composition according to claim 1 , wherein said composition is an antibody comprising:
a) a heavy chain comprising said VH; and
b) a light chain comprising said VL.

7. The composition according to claim 6 , wherein said heavy chain comprises said variable heavy domain and a heavy constant domain selected from the group consisting of the heavy constant domains of human IgG1, IgG2 and IgG4, or variants thereof.

8. The composition according to claim 7 , wherein said heavy constant domain is the heavy constant domain of human IgG1.

9. The composition according to claim 8 , wherein said heavy constant domain is a variant of the heavy constant domain of human IgG1.

10. The composition according to claim 9 , wherein said variant heavy constant domain of human IgG1 has ablated FcγR binding.

11. A nucleic acid composition encoding said composition according to claim 7 , wherein said nucleic acid composition comprises:
a) a first nucleic acid encoding said first polypeptide; and
b) a second nucleic acid encoding said second polypeptide.

12. A nucleic acid composition comprising a nucleic acid encoding said composition according to claim 4 .

13. An expression vector composition comprising said nucleic acid of claim 12 .

14. An expression vector composition comprising said first and second nucleic acids of claim 11 .

15. An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid of claim 11 ; and
b) a second expression vector comprising said second nucleic acid of claim 11 .

16. A host cell comprising said expression vector composition according to claim 13 .

17. A method of making a composition comprising an anti-CD38 antigen binding domain, comprising culturing said host cell of claim 16 under conditions wherein said composition comprising the anti-CD38 binding domain is expressed, and recovering said composition.

18. A method of treating multiple myeloma comprising administering to a subject in need thereof an effective amount of said composition according to claim 1 .

19. A method of treating multiple myeloma comprising administering to a subject in need thereof an effective amount of said composition according to claim 2 .

20. A method of treating multiple myeloma comprising administering to a subject in need thereof an effective amount of said composition according to claim 3 .

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Elias Kathleen Ann
• Landes Gregory
• Singh Shweta
• Korver Wouter
• Drake Andrew Walling
• Haak-Frendscho Mary
• Bhaskar Vinay
• Willert Erin

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title